Overview

Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery

Status:
Completed
Trial end date:
2010-03-09
Target enrollment:
0
Participant gender:
All
Summary
This study is conducted in Japan. The aim of this non-interventional study is to investigate the safety and effectiveness of treatment with eptacog alpha (NovoSeven®) when undergoing surgery under normal clinical practice conditions.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Factor VIII
Criteria
Inclusion Criteria:

- Patients with haemophilia A and B with inhibitors who received eptacog alpha
(NovoSeven®) as treatment when undergoing surgery

Exclusion Criteria:

- Patients who was not deemed to be appropriate to the treatment of eptacog alpha
(NovoSeven®)